Advertisement

International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 855–862 | Cite as

The need for community pharmacists in oncology outpatient care: a systematic review

  • Johannes Thoma
  • Romána ZelkóEmail author
  • Balázs Hankó
Research Article

Abstract

Background One-third of all deaths in Europe each year are attributable to cancer. Issues relating to cancer care, therefore, will continue to expand. To manage the increased challenges—including doctor shortages, an ageing population, and rural distribution of supplies—community pharmacists will likely be required to assume responsibility within oncology care. Aim of the review To assess the need for further investigation into quantity and utility of community pharmacists’ interventions in assisting oncology outpatients. Methods Initial search terms for identifying relevant literature within the PubMed database were informed by four key questions. Study selection for the systematic review was performed based on inclusion and exclusion criteria, which were defined a priori using the PICO tool. Literature searches identified 2470 papers, for which titles and abstracts were reviewed. Of these, 220 papers were retained for detailed analysis. The full texts of these manuscripts were then screened by applying the inclusion criteria. The remaining 68 papers were included in the systematic review. Results Several models of pharmacists’ interventions in inpatient, medium, and outpatient care have proven to be successful, have been consistently efficacious, and have positively influenced patient outcomes. Importantly, the quantity of scientific research, and thus of reported beneficial outcomes, in outpatient care is much lower than that conducted for inpatient and medium care. Conclusion Based on our findings, we suggest that further investigation of community pharmacists’ interventions into oncology outpatient assistance is necessary, and that further research should be conducted to address this need.

Keywords

Cancer Community pharmacist Intervention Oncology Pharmaceutical Care Review 

Notes

Acknowledgments

We would like to express our thanks to Dr. Denes Kleiner for supporting the outcome search.

Funding

There were no sources of funding or other support for this systematic review.

Conflicts of interest

The authors have no conflicts of interest—financial or otherwise—to report.

Supplementary material

11096_2016_297_MOESM1_ESM.doc (44 kb)
Supplementary material 1 (DOC 6926 kb)

References

  1. 1.
    Curtis LJ, McKinnon RA, Anderson C. Palliative care is everyone’s business, including pharmacists. Am J Pharm Educ. 2013;77(2):21.CrossRefGoogle Scholar
  2. 2.
    Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high income countries. Lancet Oncol. 2011;12:933–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Hoppe-Tichy T. Current challenges in European oncology pharmacy practice. J Oncol Pharm Pract. 2010;16:1.CrossRefGoogle Scholar
  4. 4.
    Tuffaha HW, Abdelhadi O, Omar SA. Clinical pharmacy services in the outpatient pediatric oncology clinics at a comprehensive cancer center. Int J Clin Pharm. 2012;34:27–31.CrossRefPubMedGoogle Scholar
  5. 5.
    Liekweg A, Westfeld M, Jähde U. From oncology pharmacy to pharmaceutical care: new contributions to multidisciplinary cancer care. Support Care Cancer. 2004;12:73–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Barth J, Baumann L, Bismarck C, Bornemann K, Braband S, Carstens G, et al. QuapoS4 Quality standard for the oncology pharmacy service with commentary. Onkopress, 2009.Google Scholar
  7. 7.
    Chastek B, Harley C, Kallich J, Newcomer L, Paoli CJ, Teitelbaum AH. Health care costs for patients with cancer at the end of life. J Oncol Pract. 2012; 8(6s).Google Scholar
  8. 8.
    Schickedanz A. Of value: a discussion of cost, communication and evidence to improve cancer care. Oncologist. 2010;15(1):73–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Fasola G, Aita M, Marini L, Follador A, Tossolini M, Mattioni L, et al. Drug waste minimization and cost containment in medical oncology: two-year results of a feasibility study. BMC Health Serv Res. 2008;8:70.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Session JK, Valgus J, Barbour SY, Iacovell L. Role of oncology clinical pharmacists in light of the oncology workforce study. J Oncol Pract. 2010; 6(5).Google Scholar
  11. 11.
    Ise Y, Morita T, Katayama S, Kizawa Y. The activity of palliative care team pharmacists in designated cancer hospitals: a nationwide survey in Japan. J Pain Symptom Manage. 2014;47(3):588–93.CrossRefPubMedGoogle Scholar
  12. 12.
    Avery M, Williams F. The importance of pharmacist providing patient education in oncology. J Pharm Pract. 2015;28(1):26–30.CrossRefPubMedGoogle Scholar
  13. 13.
    Döhler N, Krolop L, Ringsdorf S, Meier K, Ko YD, Kuhn W, et al. Task allocation in cancer medication management—integrating the pharmacist. Patient Educ Couns. 2011;83(3):367–74.CrossRefPubMedGoogle Scholar
  14. 14.
    Yeoh TT, Si P, Chew L. The impact of medication therapy management in older oncology patients. Support Care Cancer. 2013;21:1287–93.CrossRefPubMedGoogle Scholar
  15. 15.
    Mancini R. Implementing a standardized pharmacist assessment and evaluating the role of a pharmacist in a multidisciplinary supportive oncology clinic. J. Support Oncol. 2012;10:99–106.CrossRefPubMedGoogle Scholar
  16. 16.
    Voll ML, Yap KD, Terpstra WE, Crul M. Potential drug–drug interactions between anti cancer agents and community pharmacy dispensed drugs. Pharm World Sci. 2010;32:575–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Bremberg E, Hising C, Nylen U, Ehrsson H, Eksborg S. An evaluation of pharmacist contribution to an oncology ward in a Swedish hospital. J Oncol Pharm Pract. 2006;12(2):75–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Liekweg A, Westfeld M, Braun M, Zivanovic O, Schink T, Kuhn W, et al. Pharmaceutical care for patients with breast and ovarian cancer. Support Care Cancer. 2012;20:2669–77.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    McKee M, Frei BL, Garcia A, Fike D, Soefje SA. Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic. J Oncol Pharm Pract. 2011;17(4):387–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Ibrahim NA, Björnsdottir I, Al Alwan AS, Honore PH. Insights about health related quality of life indicate demands for better pharmaceutical care. J Oncol Pharm Pract. 2014;20(4):270–7.CrossRefGoogle Scholar
  21. 21.
    Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Ekaphop S, Ratanatharathorn V. The European organization for research and treatment of cancer quality of life questionnaire (EORTC QLQ– C30): validation study of the Thai version. Qual Life Res. 2006;15:167–72.CrossRefPubMedGoogle Scholar
  22. 22.
    Kawaguchi T, Iwase S, Koinuma M, Onodera Y, Takeuchi H, Umeda M, et al. Determinants affecting quality of life: implications for pharmacist counseling for patients with breast cancer in Japan. Biol Pharm Bull. 2012;35(1):59–64.CrossRefPubMedGoogle Scholar
  23. 23.
    Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic evaluations of clinical pharmacy services: 2006–2010. Pharmacotherapy. 2014;34(8):771–93.CrossRefPubMedGoogle Scholar
  24. 24.
    Leveque D, Delpeuch A, Gourieux B. New anticancer agents: role of clinical pharmacy services. Anticancer Res. 2014;34(4):1573–8.PubMedGoogle Scholar
  25. 25.
    Delpeuch A, Leveque D, Gourieux B, Herbrecht R. Impact of clinical pharmacy services in a hematology/oncology inpatient setting. Anticancer Res. 2015;35(1):457–60.PubMedGoogle Scholar
  26. 26.
    Khanal S, Poudel A, Sharan K, Palaian S. Oncology pharmacy practice in a teaching hospital in Nepal. J Oncol Pharm Pract. 2010;16(2):75–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Walter C, Mellor JD, Rice C, Kirsa S, Ball D, Duffy M, et al. Impact of a specialist clinical cancer pharmacist at a multidisciplinary lung cancer clinic. Asia Pac J Clin Oncol. 2014. doi: 10.1111/ajco.12267.PubMedGoogle Scholar
  28. 28.
    Felton MA, van Londen G, Marcum ZA. Medication adherence to oral cancer therapy: the promising role of the pharmacist. J Oncol Pharm Pract. 2016;22(2):378–81.CrossRefPubMedGoogle Scholar
  29. 29.
    Coutsouvelis J, Corallo CE, Dooley MJ, Foo J, Whitfield A. Implementation of a pharmacist-initiated pharmaceutical handover for oncology and haematology patients being transferred to critical care units. Support Care Cancer. 2010;18(7):811–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Katayama S. The role in cancer chemotherapy of “a pharmacist specialized in cancer”. Gan To Kagaku Ryoho. 2006;33(11):1575–8.PubMedGoogle Scholar
  31. 31.
    Tuffaha HW, Koopmans SM. Development and implementation of a method for characterizing clinical pharmacy interventions and medication use in a cancer center. J Oncol Pharm Pract. 2012;18(2):180–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Inoue T. Management of pharmacists on the cancer chemotherapy. Gan To Kagaku Ryoho. 2004;31(1):11–6.PubMedGoogle Scholar
  33. 33.
    Chan A, Tan SH, Wong CM, Yap KY, Ko Y. Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. Clin Ther. 2009;31(Pt 2):2379–86.CrossRefPubMedGoogle Scholar
  34. 34.
    Arunachalam D, Thirumoorthy A, Devi S. Thennarasu. Quality of life in cancer patients with disfigurement due to cancer and its treatments. Indian J Pallait Care. 2011;17(3):184–90.CrossRefGoogle Scholar
  35. 35.
    Richardson T, O’Reilly C, Chen TF. A comprehensive review of the impact of clinical pharmacy services on patient outcomes in mental health. Int J Clin Pharm. 2014;36:222–32.CrossRefPubMedGoogle Scholar
  36. 36.
    Norrström B, Cannerfelt IB, Frid H, Roos K, Ramström H. Introduction of pharmaceutical expertise in a palliative care team in Sweden. Pharm World Sci. 2010;32(6):829–34.CrossRefPubMedGoogle Scholar
  37. 37.
    Mousavi M, Hayatshahi A, Sarayani A, Hadjibabaie M, Javadi M, Torkamandi H, et al. Impact of clinical pharmacist based parenteral nutrition service for bone marrow transplantation patients: a randomized clinical trial. Support Care Cancer. 2013;21:3441–8.CrossRefPubMedGoogle Scholar
  38. 38.
    Ryan N, Chambers C, Ralph C, England D, Cusano F. Evaluation of clinical pharmacists follow up service in an oncology pain clinic. J Oncol Pharm Pract. 2012;19(2):151–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Shah S, Dowell J, Greene S. Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Ann Pharmacother. 2006;40(9):1527–33.CrossRefPubMedGoogle Scholar
  40. 40.
    Valgus JM, Faso A, Gregory KM, Jarr S, Savage S, Caiola S, et al. Integration of a clinical pharmacist into the hematology-oncology clinics at an academic medical center. Am J Health Syst Pharm. 2011;68(7):613–9.CrossRefPubMedGoogle Scholar
  41. 41.
    Ruder AD, Smith DL, Madsen MT, Kass FH. Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic? J Oncol Pharm Pract. 2011;17(4):425–32.CrossRefPubMedGoogle Scholar
  42. 42.
    Chew C, Chiang J, Yeoh TT. Impact of outpatient interventions made at an ambulatory cancer centre oncology pharmacy in Singapore. J Oncol Pharm Pract. 2015;21(2):93–101.CrossRefPubMedGoogle Scholar
  43. 43.
    Van Den Broucke J, Verhaeghe A, Debruyne PR, Verhelle K. Value of a clinical pharmacist in the oncology department and optimalisation of the applicability of geriatric tools assessing potential inappropriate medication use in geriatric patients. J Pharm Belg. 2014;1:28–36.Google Scholar
  44. 44.
    Ishimoto K, Otsubo Y, Tamura C, Uchida Y, Ishimitsu T, Kamiya A. The role of pharmacists for promotion of cancer chemotherapy in outpatients. Yakugaku Zasshi. 2004;124(3):149–57.CrossRefPubMedGoogle Scholar
  45. 45.
    Koshita A, Nishiwaki M, Hirashima Y, Idosawa H, Lioka K, Ichikawa Y. Role of pharmacists in providing outpatient clinic cancer chemotherapy—a current status of Tokyo Metropolitan Komagome Hospital. Gan To Kagaku Ryoho. 2007;34(Suppl 2):257–9.PubMedGoogle Scholar
  46. 46.
    Iihara H, Ishihara M, Matsuura K, Kurahashi S, Takahashi T, Kawaguchi M, et al. Pharmacists contribute to the improved efficiency of medical practises in the outpatient cancer chemotherapy clinic. J Eval Clin Pract. 2012;18:753–60.CrossRefPubMedGoogle Scholar
  47. 47.
    Paul M, Davey B, Senf B, Stoll C, Münstedt K, Mücke R, et al. Patients with advanced cancer and their usage of complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;139:1515–22.CrossRefPubMedGoogle Scholar
  48. 48.
    de Lemos ML. Pharmacist’s role in meeting the psychosocial needs of cancer patients using complementary therapy. Psycho–Oncology. 2005;14:204–10.CrossRefPubMedGoogle Scholar
  49. 49.
    Atayee RS, Best BM, Daniels CE. Development of an ambulatory palliative care pharmacist practice. J Palliat Med. 2008;11(8):1077–82.CrossRefPubMedGoogle Scholar
  50. 50.
    Smith MB, Gumpper KF, Riebandt G, Handel EM. Implementation of the pharmacy practice model initiative within comprehensive cancer centers. Am J Health Syst Pharm. 2014;71(19):1647–60.CrossRefPubMedGoogle Scholar
  51. 51.
    Edwards SJ, Abbott R, Edwards J, LeBlanc M, Dranitsaris G, Donnan J, et al. Outcomes assessment of a pharmacist-directed seamless care program in an ambulatory oncology clinic. J Pharm Pract. 2014;27(1):46–52.CrossRefPubMedGoogle Scholar
  52. 52.
    Lopez-Martin C, Garrido Siles M, Alcaide-Garcia J, Faus Felipe V. Role of clinical pharmacists to prevent drug interactions in cancer outpatients: a single-centre experience. Int J Clin Pharm. 2014;36(6):1251–9.CrossRefPubMedGoogle Scholar
  53. 53.
    Shamieh O, Hui D. A comprehensive palliative care program at a tertiary cancer center in Jordan. Am J Hosp Palliat Care. 2015;32(2):238–42.CrossRefPubMedGoogle Scholar
  54. 54.
    Gagnon L, Fairchild A, Pituskin E, Dutka J, Chambers C. Optimizing pain relief in a specialized outpatient palliative radiotherapy clinic: contributions of a clinical pharmacist. J Oncol Pharm Pract. 2012;18(1):76–83.CrossRefPubMedGoogle Scholar
  55. 55.
    Tralongo P, Ferrau F, Borsellino N, Verderame F, Caruso M, Giuffrida D, et al. Cancer patient-centered home care: a new model for health care in oncology. Ther Clin Risk Manag. 2011;7:387–92.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Tait PA, Gray J, Hakendorf P, Morris B, Currow DC, Rowett DS. Community pharmacists: a forgotten resource for palliative care. BMJ Support Palliat Care. 2013;3(4):436–43.CrossRefPubMedGoogle Scholar
  57. 57.
    O’Connor M, Hewitt LY, Tuffin PH. Community pharmacists’ attitudes toward palliative care: an Australian nationwide survey. J Palliat Med. 2013;16(12):1575–81.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Kato T. The role of home palliative care by health insurance pharmacy. Gan To Kagaku Ryoho. 2011;38(Suppl 1):56–8.PubMedGoogle Scholar
  59. 59.
    Hussainy SY, Beattie J, Nation RL, Dooley MJ, Fleming J, Wein S, et al. Palliative care for patients with cancer: what are the educational needs of community pharmacists? Support Care Cancer. 2006;14(2):177–84.CrossRefPubMedGoogle Scholar
  60. 60.
    Akai N, Fujita-Hamabe W, Tokuyama S. Attitude survey of medical staff on the participation of community pharmacists in palliative home care. Yakugaku Zasshi. 2009;129(11):1393–401.CrossRefPubMedGoogle Scholar
  61. 61.
    Hussainy SY, Marriott JL, Beattie J, Nation RL, Dooley MJ. A palliative cancer care flexible education program for Australian community pharmacists. Am J Pharm Educ. 2010;74(2):24.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Savage I, Blenkinsopp A, Closs SJ, Bennett MI. ‘Like doing a jigsaw with half the parts missing’: community pharmacists and the management of cancer pain in the community. Int J Pharm Pract. 2013;21(3):151–60.CrossRefPubMedGoogle Scholar
  63. 63.
    O’Connor M, Pugh J, Jiwa M, Hughes J, Fisher C. The palliative care interdisciplinary team: where is the community pharmacist? J Palliat Med. 2011;14(1):7–11.CrossRefPubMedGoogle Scholar
  64. 64.
    Takagi M. Pharmacists in community medicine: especially in cancer treatment. Yakugaku Zasshi. 2011;131(1):45–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Satoh H, Miki A, Maejima K, Iizuka K, Yamaga S, Sakashita K, et al. Problems of collaboration between community and hospital pharmacists for cancer chemotherapy and proposed corrective measures: KJ method based identification and planning workshop. Yakugaku Zasshi. 2014;134(4):563–74.CrossRefPubMedGoogle Scholar
  66. 66.
    Katori C, Tamura Y, Nishimura K, Karasawa J, Kushida K. The role of pharmacists involved in drug therapy for home-care patients with the end-stage cancer. Gan to kagaku ryoho. Cancer Chemother. 2007;34(2):232–5.Google Scholar
  67. 67.
    Suzuki M, Sato M, Okazawa M, Sakata S, Orii T. Benefits of pharmacists’ assessment of outpatients undergoing Chemotherapy. Gan To Kagaku Ryoho. 2010;37(13):2881–5.PubMedGoogle Scholar
  68. 68.
    Needham DS, Wong IC, Campion PD, Hull and east riding pharmacy development group. Evaluation of the effectiveness of UK community pharmacists’ interventions in community palliative care. Palliat Med. 2002;16(3):219–25.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Johannes Thoma
    • 1
  • Romána Zelkó
    • 1
    Email author
  • Balázs Hankó
    • 1
  1. 1.University Pharmacy Department of Pharmacy AdministrationSemmelweis UniversityBudapestHungary

Personalised recommendations